OKYO Pharma Ltd (OKYO) 시세

OKYO................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783

BCAB under $2

BCAB under $2

Insider buy: On September 5, 2024, OKYO Pharma LTD (the “Company”) issued this 6K announcing today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 80,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.15 per share. This brings the total shareholding of Mr Cerrone to 9,801,570 shares which is 28.97% of issued share capital.

..got FDA patent.. news traveling slowly.. OKYO$...

OKYO under $2

..buy..buy..buy... OKYO$ ...

Okyo Pharma Gets US Patent for Potential Treatment of Dry Eye Disease Symptoms

10:23 AM EDT, 08/27/2024 (MT Newswires) -- Okyo Pharma (OKYO) said Tuesday it received a US patent for OK-101 to treat symptoms of dry eye disease.

The patent, issued Aug. 6, covers the use of OK-101 to treat irritated, burning eyes and blurred vision in patients with dry eye disease, according to the company.

OKYO................................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
August 06 2024 - 7:00AM

Alert
Print
Share On Facebook

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key European Patent entitled: “Compositions Comprising Chemerin Analogs and Methods of Use”. The present disclosure that lists Raj Patil, Chief Scientific Officer of OKYO Pharma as a joint Inventor, relates to novel OK-101 chemerin analogs for use in treating various diseases and conditions including but not limited to, ocular inflammatory and pain conditions, strengthening the Company’s intellectual property position in this field.
"We are delighted with the issuance of this European patent, which underscores the innovative nature of our OK-101 chemerin analogs and their therapeutic potential. This milestone strengthens our intellectual property portfolio and positions OKYO Pharma for continued advancement in addressing significant unmet medical needs," commented Dr. Gary S. Jacob, Ph.D., CEO of OKYO. “The issuance of this patent further solidifies OKYO Pharma's commitment to advancing novel therapies that aim to improve outcomes for patients suffering from ocular pain and inflammation. The company continues to explore strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates.”

About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.

About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.

Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Enquiries:

OKYO Pharma Limited

Gary S. Jacob, Chief Executive Officer 917-497-7560
Business Development &
Investor Relations Paul Spencer +44 (0)20 7495 2379

Added at one dollar today, patience OKYO$ ...

OKYO under $2

OKYO under $2

OKYO............................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783

OKYO under $2

...loading zone OKYO$$ imo, $1.30's, glta...

CONFIRMED REPEATED NEWS, SAME HAPPENED WITH BNOX YESTERDAY******MARKET WILL DICTATE WAY FORWARD*****TREAD CAREFULLY

HAPPY WEEKEND TO YOU AND YOURS***GREETINGS

okyo 1.99 news OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 $OKYO https://t.co/tgjKEzE3jP— Health Stocks News (@health_stocks) March 22, 2024

OKYO under $2

OKYO 10Q due March 14

OKYO 10Q due March 7

OKYO under $2

EXIT...LOOKS LIKE DILUTION INTO NEWS

OKYO DAY TRADER

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need
The initial trial of OK-101 to treat NCP is designed as a randomized, placebo-controlled, double-masked Phase 2 clinical trial and is planned to begin in 2Q 2024
NCP is an Orphan disease as listed in the National Organization for Rare Disorders
LONDON and NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared OK-101 as its first Investigational New Drug (IND) application for the treatment of NCP.

Notably, the initial IND submission to FDA proposed an open-label design for the clinical trial. Based on positive feedback from FDA, the Phase 2 study is now designed as a double-masked, randomized, 12-week placebo-controlled trial comparing OK-101 to placebo in NCP patients. A total of 54 patients are planned for the study, with NCP disease confirmed via confocal microscopy. The primary endpoint will be measured utilizing VAS pain relief scores. These protocol changes will enable a statistically valid demonstration of a true drug effect of OK-101 on NCP symptoms. OKYO Pharma is scheduling this trial to begin in Q2 2024.

The OK-101 trial, designed as a single-center trial, will be led by Pedram Hamrah, MD, of Tufts Medical Center, as Principal Investigator. Dr. Hamrah is Professor and Vice Chair of Research and Academic Programs, Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at Tufts Medical Center. An ophthalmologist and a clinician-scientist, Dr. Hamrah is a leading expert in NCP and co-inventor on the OK-101 patent. He is also a member of OKYO’s Scientific Advisory Board.

“I am very pleased that we have gained FDA IND clearance for the first drug to be tested for NCP, a debilitating disease,” said Dr. Hamrah. “Receiving the IND clearance in an important and novel indication was not a trivial hurdle to overcome. Now that the path has been opened for drugs to be tested in NCP, I am looking forward to working with the OKYO team to launch this important trial.”

“We are pleased to gain IND clearance for OK-101 to treat NCP as a second important disease target for the Company,” said Dr. Gary S. Jacob, CEO of OKYO. “OK-101 recently demonstrated favorable tolerability in a Phase 2 trial of dry eye patients along with statistically significant improvements in dry eye symptoms such as stinging/burning and blurred vision, which are also hallmarks of NCP. OK-101 was also shown in a cutting-edge mouse model of NCP to significantly reduce ocular neuropathic pain. We are looking forward to advancing OK-101 to potentially treat NCP, a chronically painful ocular disease with no FDA-approved therapy and a major unmet medical need for patients suffering from this condition.”

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Early still here

..bailed w a profit lol ...

I don't remember what $2 looks like

Really, looks like 2 bucks.

bet the first time that ever happened to you ...lol

..frustrating..Had limit order $3.05..now $2ish, important cure, OKYO$..gl...

Amazing...clinical trial is favorable but pps keeps going down...go figure

Big volume, just needed to take a breathe before we move further up the ladder imo

Will end up green today

Will be over $3 by Monday...

Got to add down here...could be a $75-100 play before Y/E

..thought it make $3..sell the news, terrible.. OKYO$...

Got some $2.35s...deal

Bought more this morning...luv sales

https://ih.advfn.com/stock-market/NASDAQ/okyo-pharma-OKYO/stock-news/92205380/form-6-k-report-of-foreign-issuer-rules-13a-16

Looks like we're seeing it $$ been a phenomenal week

OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")

https://www.globenewswire.com/news-release/2023/10/05/2755253/0/en/OKYO-Pharma-Announces-Positive-Safety-Data-Profile-for-the-ongoing-OK-101-Phase-2-Clinical-Trial-to-Treat-Dry-Eye-Disease-DED.html

$OKYO

Up to 3.5$ pre market this morning let's go !! OKYO

3$+ is the next stop

Nice little ore market action

$OKYO Video - Corporate Profile on OKYO Pharma Ltd (Nasdaq: OKYO)

Excellent close!! Once 2.50 broke that was it

https://news.squeezereport.com/short-squeeze/okyo-pharma-limited-nasdaq-okyo-short-squeeze-2023-10-04/